Clinical Trial Detail

NCT ID NCT04188405
Title Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic myeloid leukemia

acute myeloid leukemia

Therapies

Decitabine + Ponatinib + Venetoclax

Age Groups: senior adult

No variant requirements are available.